InvestorsHub Logo

lesgetrich

04/22/18 1:29 PM

#22522 RE: wallstreetbuyer #22499

Les, if you to write the article now, any change you want to make about OMHE valuation?



My last paragraph on Omni in that article sums it up...

https://seekingalpha.com/instablog/12862651-les-mezei/5093661-four-long-term-penny-stock-picks-2017-gained-354-percent-still-buy" rel="nofollow" target="_blank" >https://seekingalpha.com/instablog/12862651-les-mezei/5093661-four-long-term-penny-stock-picks-2017-gained-354-percent-still-buy[tag]Four Long Term Penny Stock Picks For 2017 Gained 354% - Still A Buy
[/tag]

I believe that this company, as of today, is significantly undervalued. If they are on path next summer for $16.5 million in revenue, I would target them for a pps of at least $.13/share. It could be more than double that if they complete their share restructuring. If we start seeing some real progress on their pharma grade drug, share appreciation could be huge. Consequently, I am again recommending them for a long term hold.



There are a lot of "if's" in there. So far we haven't gotten any answers. Until we do, I can't recommend a "Buy" but there is also no reason yet to change from a "hold" other than confidence in Andrey's management.